Results 161 to 170 of about 7,833 (210)

Is Brukinsa (Zanubrutinib) a Safer Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia? A Systematic Review and Meta-Analysis. [PDF]

Pharmaceuticals (Basel)
Hetta HF, Salama A, Aljuaid TA, Mojmami YT, Alotibi RS, Alqabaly AM, Aldosari NA, Alshahri SA, Asiri WIA, Alamri RS, Alanazi FA, Alenazi MSA, Albuhayri MH, Ramadan YN, Sayad R.   +14 more
europepmc   +1 more source

Spleen and Bruton's tyrosine kinase inhibitors for the management of adult immune thrombocytopenia: A systematic review and meta-analysis of randomized controlled trials. [PDF]

Clin Hematol Int
Vatvani AD, Hariyanto TI, Ramirez AC, Shabarek N.   +3 more
europepmc   +1 more source

Comparison of One-Year Adverse Events Between First- and Second-Generation Bruton's Tyrosine Kinase Inhibitors: A Retrospective Study. [PDF]

Cureus
Ito A, Ito K, Iriyama C, Goto N, Inamoto Y, Okamoto M, Hirose Y, Morisaku M, Yamada S, Hayakawa N, Tomita A.   +10 more
europepmc   +1 more source

Modulating the Binding Kinetics of Bruton's Tyrosine Kinase Inhibitors through Transition-State Effects. [PDF]

J Am Chem Soc
Bravo E, Li Y, Lin DY, Srinivasan B, Barone M, Li SX, DelloRusso F, Rahiyanath AS, Corrionero A, Alfonso P, Prendiville N, Kozakov D, Andreotti AH, Tonge PJ.   +13 more
europepmc   +1 more source

The new Bruton's tyrosine kinase inhibitors SPA8007 and SPA8009 reduce stemness and invasiveness of patient-derived glioblastoma tumorspheres. [PDF]

Transl Oncol
Jo E, Lee E, Oh Y, Lee D, Lee B, Kim K, Choi RJ, Hong J, Jeon Y, Cho H, Choi YS, Kim S, Won SY, Choi S, Roh TH, Moon JH, Kim EH, Chang JH, Jeon R, Kang SG.   +19 more
europepmc   +1 more source

Cost impact of Bruton's tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia. [PDF]

J Comp Eff Res
Kittai AS, Patel DA, Shafrin J, Zawadzki N, Shetty VS, Barqawi YK, Rhodes JM.   +6 more
europepmc   +1 more source

Bruton's Tyrosine Kinase (BTK) Mutations in Chronic Lymphocytic Leukemia (CLL): A Clinical View. [PDF]

Mediterr J Hematol Infect Dis
Molica S, Allsup D.
europepmc   +1 more source

The role of microglia in multiple sclerosis: implications for treatment with Bruton's tyrosine kinase inhibitors. [PDF]

Front Immunol
Vermersch P, Airas L, Berger T, Deisenhammer F, Grigoriadis N, Hartung HP, Magyari M, Popescu V, Pozzilli C, Pugliatti M, Van Wijmeersch B, Zakaria M, Oreja-Guevara C.   +12 more
europepmc   +1 more source